Although the results from the phase II CABOSUN trial were intriquing, I would not consider cabozantinib as first line therapy for patients with intermediate or poor-risk mRCC. There were a number of concerning results. Firstly, the extremely low PFS of ~5months in the sunitinib-treated pat...